Kyou, Yoshitaka
Yasui-Furukori, Norio
Hasegawa, Naomi
Ide, Kenta
Ichihashi, Kayo
Hashimoto, Naoki
Hori, Hikaru
Shimizu, Yoshihito
Imamura, Yayoi
Muraoka, Hiroyuki
Iida, Hitoshi
Ohi, Kazutaka
Yasuda, Yuka
Ogasawara, Kazuyoshi
Numata, Shusuke
Iga, Jun-ichi
Tsuboi, Takashi
Ochi, Shinichiro
Kodaka, Fumitoshi
Furihata, Ryuji
Onitsuka, Toshiaki
Makinodan, Manabu
Komatsu, Hiroshi
Takeshima, Masahiro
Kubota, Chika
Hishimoto, Akitoyo
Atake, Kiyokazu
Yamagata, Hirotaka
Kido, Mikio
Nagasawa, Tatsuya
Usami, Masahide
Kishimoto, Taishiro
Kikuchi, Saya
Matsumoto, Junya
Miura, Kenichiro
Yamada, Hisashi
Watanabe, Koichiro
Inada, Ken
Hahimoto, Ryota
Funding for this research was provided by:
JSPS KAKENHI (JP21K17261)
Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201)
Japan Agency for Medical Research and Development (JP16dk0307060, JP19dk0307083, and JP22dk0307112)
The Japanese Society of Neuropsychopharmacology
The Japanese Society of Mood Disorders
The Japanese Society of Clinical Neuropsychopharmacology
The Japanese Society of Psychiatry and Neurology
Article History
Received: 1 September 2022
Accepted: 16 December 2022
First Online: 26 December 2022
Declarations
:
: This study was approved by the ethics committees of the National Center for Neuropsychiatry (approval number B2022-004) and Neurology and at the participating EGUIDE sites.
: Not applicable.
: The authors declare no conflict of interest.